# US 2021/0196724 A1 · Biaryl compositions and methods for modulating a kinase cascade

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0196724 A1
- Document ID: US20210196724A1
- Status: Published application
- Kind: A1
- Application number: 17/187,980
- Filed: 2021-03-01
- Published: 2021-07-01
- Earliest claimed: 2016-08-12
- Assignees: Athenex, Inc.
- Applicants: Athenex, Inc.
- Inventors: Michael P. SMOLINSKI; Nader N. NASIEF ABDEL SAYED; David G. HANGAUER, JR.
- Web page: https://patentgrep.com/patent/US20210196724A1

## CPC

- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61P 27/02: Ophthalmic agents
- A61P 35/00: Antineoplastic agents
- C07C 233/13: with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C 233/22: having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
- C07D 213/56: Amides
- C07D 213/64: attached in position 2 or 6
- C07D 213/74: Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C07D 239/34: One oxygen atom
- C07D 401/10: linked by a carbon chain containing aromatic rings
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/10: linked by a carbon chain containing aromatic rings
- C07D 413/14: containing three or more hetero rings
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0085: {Brain, e.g. brain implants; Spinal cord}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The application relates to biaryl compounds, pharmaceutical compositions comprising the compounds, and methods of use the compounds for treating cell proliferation disorders.

## Claims

### Claim 1

A method of treating or preventing a cancer, comprising administering to a subject in need thereof an effective amount of a compound of formula (A):
or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein:
Xa is CRa or N;
Xb is CRb or N;
Xc is CRc or N;
Xd is CRd or N;
Ra is H, halogen, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl;
Rb is H, halogen, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl;
Rc is H, halogen, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl;
Rd is H, halogen, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl;
R1 and R2 are each independently H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, or O−(C1-C6 alkyl);
alternatively, R1 and R2, together with the carbon atom to which they are attached, form a 3-8 membered saturated, unsaturated, or partially saturated carbocycle, or a saturated, unsaturated, or partially saturated heterocycle comprising one or two 5-7 membered rings and one or more heteroatoms selected from N, O, and S;
alternatively, one of R1 and R2, together with the carbon atom to which R1 or R2 is attached and
form a 7-12 membered saturated, unsaturated, or partially saturated carbocycle, or a 7-12 membered saturated, unsaturated, or partially saturated heterocycle comprising one or more heteroatoms selected from N, O and S;
R3 and R4 are each independently (a) H, (b) halogen, (c) OH, (d) COOH, (e) CONH2, (f) NHCOR101, (g) NR101COR102, (h) S(O)tR101, (i) C1-C6 alkyl, (j) C2-C6 alkenyl, (k) C2-C6 alkynyl, (l) O—(C1-C6 alkyl), (m) O—(C2-C6 alkenyl), (n) O—(C2-C6 alkynyl), (o) COO—(C1-C6 alkyl), (p) COO—(C2-C6 alkenyl), (q) COO—(C2-C6 alkynyl), (r) CONH—(C1-C6 alkyl), (s) CONH—(C2-C6 alkenyl), (t) CONH—(C2-C6 alkynyl), (u) CON(C1-C6 alkyl)2, (v) CON(C2-C6 alkenyl)2, (w) CON(C2-C6 alkynyl)2, (x) (C1-C6 alkyl)-NH2, (y) (C2-C6 alkenyl)-NH2, (z) (C2-C6 alkynyl)u-NH2, (aa1) (C1-C6 alkyl)v-NH(C1-C6 alkyl), (aa2) (C1-C6 alkyl)v-NH(C2-C6 alkenyl), (aa3) (C1-C6 alkyl)v-NH(C2-C6 alkynyl), (bb1) (C2-C6 alkenyl)v-NH(C1-C6 alkyl), (bb2) (C2-C6 alkenyl)v-NH(C2-C6 alkenyl), (bb3) (C2-C6 alkenyl)v-NH(C2-C6 alkynyl), (cc) (C2-C6 alkynyl)v-NH(C1-C6 alkyl), (cc2) (C2-C6 alkynyl)v-NH(C2-C6 alkenyl), (cc3) (C2-C6 alkynyl)-NH(C2-C6 alkynyl), (dd1) (C1-C6 alkyl)w-N(C1-C6 alkyl)2, (dd2) (C1-C6 alkyl)w-N(C2-C6 alkenyl)2, (dd3) (C1-C6 alkyl)w-N(C2-C6 alkynyl)2, (ee1) (C2-C6 alkenyl)w-N(C1-C6 alkyl)2, (ee2) (C2-C6 alkenyl)w-N(C2-C6 alkenyl)2, (ee3) (C2-C6 alkenyl)w-N(C2-C6 alkynyl)2, (ff1) (C2-C6 alkynyl)w-N(C1-C6 alkyl)2, (ff2) (C2-C6 alkynyl)w-N(C2-C6 alkenyl)2, (ff3) (C2-C6 alkynyl)w-N(C2-C6 alkynyl)2, (gg) 3-8 membered saturated, unsaturated, or partially saturated carbocycle, or (hh) 3-8 membered saturated, unsaturated, or partially saturated heterocycle, wherein each of (i)-(hh) is optionally substituted with one or more R7;
represents a saturated, unsaturated, or partially saturated carbocycle comprising one or two 3-8 membered rings, or a saturated, unsaturated, or partially saturated heterocycle comprising one or two 5-8 membered rings and one or more heteroatoms selected from N, O and S, wherein the two 3-8 membered rings or the two 5-8 membered rings can form a fused or bridged ring structure;
represents an aromatic, saturated, unsaturated, or partially saturated carbocycle comprising one or two 3-8 membered rings, or an aromatic, saturated, unsaturated, or partially saturated heterocycle comprising one or two 5-8 membered rings and one or more heteroatoms selected from N, O and S, wherein the two 3-8 membered rings or the two 5-8 membered rings can form a fused or bridged ring structure;
each R5 is independently (a) halogen, (b) OH, (c) CONH2, (d) COOH, (e) CN, (f) N3, (g) C1-C6 alkyl, (h) C2-C6 alkenyl, (i) C2-C6 alkynyl, (j) O—(C1-C6 alkyl), (k) O—(C2-C6 alkenyl), (l) O—(C2-C6 alkynyl), (m) COO—(C1-C6 alkyl), (n) COO—(C2-C6 alkenyl), (o) COO—(C2-C6 alkynyl), (p) CONH—(C1-C6 alkyl), (q) CONH—(C2-C6 alkenyl), (r) CONH—(C2-C6 alkynyl), (s) CON(C1-C6 alkyl)2, (t) CON(C2-C6 alkenyl)2, (u) CON(C2-C6 alkynyl)2, (vi) (C1-C6 alkyl)v-NH(C1-C6 alkyl), (v2) (C1-C6 alkyl)v-NH(C2-C6 alkenyl), (v3) (C1-C6 alkyl)v-NH(C2-C6 alkynyl), (w1) (C2-C6 alkenyl)v-NH(C1-C6 alkyl), (w2) (C2-C6 alkenyl)-NH(C2-C6 alkenyl), (w3) (C2-C6 alkenyl)v-NH(C2-C6 alkynyl), (x1) (C2-C6 alkynyl)v-NH(C1-C6 alkyl), (x2) (C2-C6 alkynyl)v-NH(C2-C6 alkenyl), (x3) (C2-C6 alkynyl)v-NH(C2-C6 alkynyl), (y1) (C1-C6 alkyl)w-N(C1-C6 alkyl)2, (y2) (C1-C6 alkyl)w-N(C2-C6 alkenyl)2, (y3) (C1-C6 alkyl)w-N(C2-C6 alkynyl)2, (z1) (C2-C6alkenyl)w-N(C1-C6 alkyl)2, (z2) (C2-C6 alkenyl)w-N(C2-C6 alkenyl)2, (z3) (C2-C6 alkenyl)w-N(C2-C6 alkynyl)2, (aa1) (C2-C6 alkynyl)w-N(C1-C6 alkyl)2, (aa2) (C2-C6 alkynyl)w-N(C2-C6 alkenyl)2, (aa3) (C2-C6 alkynyl)w-N(C2-C6 alkynyl)2, (bb) S—(C1-C6 alkyl), (cc) S(O)—(C1-C6 alkyl), (dd) S(O)2—(C1-C6 alkyl), (ee) S—(C2-C6 alkenyl), (ff) S(O)—(C2-C6 alkenyl), (gg) S(O)2—(C2-C6 alkenyl), (hh) S—(C2-C6 alkynyl), (ii) S(O)—(C2-C6 alkynyl), (jj) S(O)2—(C2-C6 alkynyl), (kk) an aromatic, saturated, unsaturated, or partially saturated carbocycle comprising one or two 3-8 membered rings, or (ll) an aromatic, saturated, unsaturated, or partially saturated heterocycle comprising one or two 5-7 membered rings and one or more heteroatoms selected from N, O and S, wherein each of (g)-(ll) is optionally substituted with one or more R8;
each R6 is independently (a) halogen, (b) OH, (c) CONH2, (d) COOH, (e) CN, (f) N3, (g) C1-C6 alkyl, (h) C2-C6 alkenyl, (i) C2-C6 alkynyl, (j) O—(C1-C6 alkyl), (k) O—(C2-C6 alkenyl), (l) O—(C2-C6 alkynyl), (m) COO—(C1-C6 alkyl), (n) COO—(C2-C6 alkenyl), (o) COO—(C2-C6 alkynyl), (p) CONH—(C1-C6 alkyl), (q) CONH—(C2-C6 alkenyl), (r) CONH—(C2-C6 alkynyl), (s) CON(C1-C6 alkyl)2, (t) CON(C2-C6 alkenyl)2, (u) CON(C2-C6 alkynyl)2, (v1) (C1-C6 alkyl)v-NH(C1-C6 alkyl), (v2) (C1-C6 alkyl)v-NH(C2-C6 alkenyl), (v3) (C1-C6 alkyl)v-NH(C2-C6 alkynyl), (w1) (C2-C6 alkenyl)v-NH(C1-C6 alkyl), (w2) (C2-C6 alkenyl)v-NH(C2-C6 alkenyl), (w3) (C2-C6 alkenyl)v-NH(C2-C6 alkynyl), (x1) (C2-C6 alkynyl)v-NH(C1-C6 alkyl), (x2) (C2-C6 alkynyl)v-NH(C2-C6 alkenyl), (x3) (C2-C6 alkynyl)v-NH(C2-C6 alkynyl), (y1) (C1-C6 alkyl)w-N(C1-C6 alkyl)2, (y2) (C1-C6 alkyl)w-N(C2-C6 alkenyl)2, (y3) (C1-C6 alkyl)w-N(C2-C6 alkynyl)2, (z1) (C2-C6 alkenyl)w-N(C1-C6 alkyl)2, (z2) (C2-C6 alkenyl)w-N(C2-C6 alkenyl)2, (z3) (C2-C6 alkenyl)w-N(C2-C6 alkynyl)2, (aa1) (C2-C6 alkynyl)w-N(C1-C6 alkyl)2, (aa2) (C2-C6 alkynyl)w-N(C2-C6 alkenyl)2, (aa3) (C2-C6 alkynyl)w-N(C2-C6 alkynyl)2, (bb) S—(C1-C6 alkyl), (cc) S(O)—(C1-C6 alkyl), (dd) S(O)2—(C1-C6 alkyl), (ee) S—(C2-C6 alkenyl), (ff) S(O)—(C2-C6 alkenyl), (gg) S(O)2—(C2-C6 alkenyl), (hh) S—(C2-C6 alkynyl), (ii) S(O)—(C2-C6 alkynyl), (jj) S(O)2—(C2-C6 alkynyl), (kk) an aromatic, saturated, unsaturated, or partially saturated carbocycle comprising one or two 3-8 membered rings, or (ll) an aromatic, saturated, unsaturated, or partially saturated heterocycle comprising one or two 5-7 membered rings and one or more heteroatoms selected from N, O and S, wherein each of (g)-(ll) is optionally substituted with one or more R9;
each R7 is independently halogen, OH, O—(C1-C6 alkyl), COO—(C1-C6 alkyl), CONH—(C1-C6 alkyl), CON(C1-C6 alkyl)2, COOH, CN, N3, 5-6 membered saturated, unsaturated, or partially saturated carbocycle, or 5-6 membered saturated, unsaturated, or partially saturated heterocycle comprising one or more heteroatoms selected from N, O and S;
each R8 is independently halogen, OH, O—(C1-C6 alkyl), C1-C6 haloalkyl, COO—(C1-C6 alkyl), CONH—(C1-C6 alkyl), CON(C1-C6 alkyl)2, COOH, CN, N3, 5-6 membered saturated, unsaturated, or partially saturated carbocycle, or 5-6 membered saturated, unsaturated, or partially saturated heterocycle comprising one or more heteroatoms selected from N, O and S;
each R9 is independently halogen, OH, O—(C1-C6 alkyl), COO—(C1-C6 alkyl), CONH—(C1-C6 alkyl), CON(C1-C6 alkyl)2, COOH, CN, N3, 5-6 membered saturated, unsaturated, or partially saturated carbocycle, or 5-6 membered saturated, unsaturated, or partially saturated heterocycle comprising one or more heteroatoms selected from N, O and S;
R101 and R102 are each independently H, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl;
R11 is H, halogen, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl;
R12 is H, halogen, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl;
m is 1, 2, 3, 4, 5, or 6;
n is 0, 1, 2, 3, 4, 5, or 6;
t is 0, 1, or 2;
u is 0 or 1;
v is 0 or 1; and
w is 0 or 1,
provided that when m is 1,
is not

### Claim 2 (depends on 1)

The method of claim 1, wherein the compound is of formula (I):
or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein:
Xa is CRa or N;
Xb is CRb or N;
Xc is CRc or N;
Xd is CRd or N;
Ra is H, halogen, or C1-C6 alkyl;
Rb is H, halogen, or C1-C6 alkyl;
Rc is H, halogen, or C1-C6 alkyl;
Rd is H, halogen, or C1-C6 alkyl;
R1 and R2 are each independently H, C1-C6 alkyl, or O—(C1-C6 alkyl);
alternatively, one of R1 and R2, together with the carbon atom to which R1 or R2 is attached and
form a 7-12 membered saturated, unsaturated, or partially saturated carbocycle, or a 7-12 membered saturated, unsaturated, or partially saturated heterocycle containing one or more heteroatoms selected from N, O and S;
R3 and R4 are each independently (a) H, (b) halogen, (c) OH, (d) COOH, (e) CONH2, (f) NHCOR101, (g) NR101COR102, (h) S(O)rR101, (i) C1-C6 alkyl, (j) O—(C1-C6 alkyl), (k) COO—(C1-C6 alkyl), (l) CONH—(C1-C6 alkyl), (m) CON(C1-C6 alkyl)2, (n) (C1-C6 alkyl)-NH2, (o) (C1-C6 alkyl)v-NH(C1-C6 alkyl), (p) (C1-C6 alkyl)-N(C1-C6 alkyl)2, or (q) 5-6 membered saturated, unsaturated, or partially saturated carbocycle, wherein each of (i)-(q) is optionally substituted with one or more R7;
represents a 5-6 membered saturated, unsaturated, or partially saturated carbocycle, or a 5-6 membered saturated, unsaturated, or partially saturated heterocycle containing one or more heteroatoms selected from N, O and S;
represents a 5-6 membered aromatic, saturated, unsaturated, or partially saturated carbocycle, or a 5-6 membered aromatic, saturated, unsaturated, or partially saturated heterocycle containing one or more heteroatoms selected from N, O and S;
each R5 is independently (a) halogen, (b) OH, (c) C1-C6 alkyl, (d) C2-C6 alkenyl, (e) O—(C1-C6 alkyl), (f) COO—(C1-C6 alkyl), (g) CONH—(C1-C6 alkyl), (h) CON(C1-C6 alkyl)2, (i) COOH, (j) CN, or (k) N3, wherein each of (c)-(h) is optionally substituted with one or more R8;
each R6 is independently (a) halogen, (b) OH, (c) C1-C6 alkyl, (d) C2-C6 alkenyl, (e) O—(C1-C6 alkyl), (f) COO—(C1-C6 alkyl), (g) CONH—(C1-C6 alkyl), (h) CON(C1-C6 alkyl)2, (i) COOH, (j) CN, or (k) N3, wherein each of (c)-(h) is optionally substituted with one or more R9;
each R7 is independently halogen, OH, O—(C1-C6 alkyl), COO—(C1-C6 alkyl), CONH—(C1-C6 alkyl), CON(C1-C6 alkyl)2, COOH, CN, N3, 5-6 membered saturated, unsaturated, or partially saturated carbocycle, or 5-6 membered saturated, unsaturated, or partially saturated heterocycle containing one or more heteroatoms selected from N, O and S;
each R8 is independently halogen, OH, O—(C1-C6 alkyl), C1-C6 haloalkyl, COO—(C1-C6 alkyl), CONH—(C1-C6 alkyl), CON(C1-C6 alkyl)2, COOH, CN, N3, 5-6 membered saturated, unsaturated, or partially saturated carbocycle, or 5-6 membered saturated, unsaturated, or partially saturated heterocycle containing one or more heteroatoms selected from N, O and S;
each R9 is independently halogen, OH, O—(C1-C6 alkyl), COO—(C1-C6 alkyl), CONH—(C1-C6 alkyl), CON(C1-C6 alkyl)2, COOH, CN, N3, 5-6 membered saturated, unsaturated, or partially saturated carbocycle, or 5-6 membered saturated, unsaturated, or partially saturated heterocycle containing one or more heteroatoms selected from N, O and S;
R101 and R102 are each independently H or C1-C6 alkyl;
R11 is H, halogen, or C1-C6 alkyl;
R12 is H, halogen, or C1-C6 alkyl;
m is 1, 2, 3, 4, 5, or 6;
n is 0, 1, 2, 3, 4, 5, or 6;
t is 0, 1, or 2;
u is 0 or 1;
v is 0 or 1; and
w is 0 or 1,
provided that when m is 1,
is not

### Claim 3 (depends on 1)

The method of claim 1, wherein the compound is of formula (II) or (III):
or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein n1 is 0, 1, 2, 3, 4, or 5.

### Claim 4 (depends on 1)

The method of claim 1, wherein the compound is of the following formula:
or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein m1 is 0, 1, 2, 3, or 4; and R51 is C1-C6 alkyl, C2-C6 alkenyl, O—(C1-C6 alkyl), COO—(C1-C6 alkyl), CONH—(C1-C6 alkyl), CON(C1-C6 alkyl)2, or CN, each of which is optionally substituted with one or more R8.

### Claim 5 (depends on 1)

The method of claim 1, wherein the compound is of the following formula:
or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein:
n2 is 0, 1, 2, or 3;
n3 is 0, 1, or 2; and
A1, A2, and A3 are each independently CR61 or N, and wherein only one of A1, A2, and A3 is N; and
R61 is H or R6.

### Claim 6 (depends on 1)

The method of claim 1, wherein R5 is halogen, C1-C6 alkyl, or O-C1-C6 alkyl.

### Claim 7 (depends on 1)

The method of claim 1, wherein R6 is halogen, C1-C6 alkyl, O-C1-C6 alkyl, or CN.

### Claim 8 (depends on 1)

The method of claim 1, wherein R3 is halogen, C1-C6 alkyl, or O—(C1-C6 alkyl).

### Claim 9 (depends on 1)

The method of claim 1, wherein the compound is
or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

### Claim 10 (depends on 1)

The method of claim 1, wherein the compound is
or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 1)

The method of claim 1, wherein the compound is

### Claim 12 (depends on 1)

The method of claim 1, wherein the compound is selected from the group consisting of
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 13 (depends on 1)

The method of claim 1, wherein the compound is selected from the group consisting of:
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 14 (depends on 1)

The method of claim 1, wherein the compound is:
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 15 (depends on 1)

The method of claim 1, wherein the cancer is selected from bone cancer, bladder cancer, brain cancer, breast cancer, cervix cancer, colon cancer, esophageal cancer, gastric cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, pancreatic cancer, pharynx cancer, placenta cancer, prostate cancer, skin cancer, thyroid cancer, tongue cancer, uteral cancer, lymphoma, and leukemia.

### Claim 16 (depends on 15)

The method of claim 15, wherein the cancer is skin cancer.

### Claim 17 (depends on 16)

The method of claim 16, wherein the skin cancer is basal cell carcinoma.

### Claim 18 (depends on 16)

The method of claim 16, wherein the skin cancer is squamous cell carcinoma.

### Claim 19 (depends on 15)

The method of claim 15, wherein the cancer is brain cancer.

### Claim 20 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, and a pharmaceutically acceptable carrier.
